Articles by Abby Proch

  1. Endpoints, Procedures, And Deviations Are On The Rise — Why? 1/20/2026

    SCRS Chief Site Success Officer Jimmy Bechtel, MBA, and Tufts CSDD Executive Director Ken Getz, MBA, discuss why they're on the rise explore ways to address, and even accept, them. 

  2. Could Moving To This Swiss Life Sciences Hub Be In Your Company's Future? 1/15/2026

    Basel Area Business & Innovation CEO Christof Klöpper discusses how the Basel Area Life Sciences Supercluster supports discovery through commercialization.

  3. Working (Well) With Patient Advocates: The Sponsor POV 1/12/2026

    Aeovian CEO Allison Hulme reflects on Aeovian Pharmaceuticals' partnership with the TSC Alliance and how it’s informed research and development of their first-in-class selective mTORC1 inhibitor. 

  4. Working (Successfully) With Pharma: A PAG's Perspective 1/12/2026

    TSC Alliance President and CEO Kari Rosbeck details the patient advocacy group's unique and fruitful relationship with Aeovian Pharmaceuticals in developing the company's first-in-class selective mTORC1 inhibitor for TSC-related refractory epilepsy.

  5. How Should Scientific Focus Change In 2026? Researchers Weigh In 1/8/2026

    To kick off 2026, clinical researchers share how they think research should change in the new year.

  6. Researchers Want A Design Shake-Up In 2026 1/7/2026

    When asked what clinical research professionals should leave behind in 2025, quite a few lamented the stale, even problematic, approach to clinical trial design. Here's what they want done differently in 2026.

  7. No Surprise Here: Experts Value Clinical Relevance Over Statistical Relevance 12/31/2025

    Experts weighed in: “Agree or disagree? Statistical significance is preferable to clinical relevance.”

  8. Trial Matching, Source Data, And More: How Clinical Researchers Used AI In 2025 12/30/2025

    Researchers reflect on the past year and share how they used AI for clinical research in 2025.

  9. What Can We Expect From The FDA In 2026? 10/20/2025

    Expert panelists at the 2025 RAPS Convergence discussed what lies ahead for the FDA in 2026.

  10. Diverse Enrollment — Ahem, "Biological Variability" — Gets Widespread Support At RAPS Convergence 10/16/2025

    DEI, diverse enrollment, biological variability -- whatever you call it, industry leaders at RAPS Convergence discussed their unwavering support of it when it comes to executing clinical trials that align "good science" with "the right thing to do."